Journal: International Journal of Molecular Sciences

Article Title: Recombinant FGF21 Attenuates Polychlorinated Biphenyl-Induced NAFLD/NASH by Modulating Hepatic Lipocalin-2 Expression

doi: 10.3390/ijms23168899

Figure Lengend Snippet: PCB exposure induces NAFLD/NASH in mice fed either a SD and a HFD. Eight-week-old male C57BL/6 mice were fed either a SD or HFD for four weeks and then treated with vehicle (corn oil), Aroclor1260 (20 mg/kg) or PCB126 (5 mg/kg) by intraperitoneal injection for a total of four injections (two, three, four, and five weeks) during the six-week study duration. ( A ) Experimental design. ( B ) Representative images of H&E staining of liver tissue. Scale bar: 50 µm. ( C ) Quantification of the lipid droplet area in H&E-stained liver tissue. The data are expressed as a percentage of the area of lipid droplets in the field. ( D ) Hepatic TG. ( E ) Hepatic FFA. ( F ) Plasma FGF21. ( G ) ORO staining showing that both Aroclor1260 (20 μM) and PCB126 (10 μM) accelerated hepatic lipid accumulation in O/P-treated human ARE primary hepatocytes. Scale bar: 50 µm. ( H ) Representative images of H&E staining of adipose tissue. The crown-like structure is illustrated by the asterisk. Scale bar: 50 µm. ( I ) Average adipocyte size of eWAT was measured in H&E images using ImageJ 1.53 s. ( J ) Quantitative analysis of CLS formation in adipose tissue. All values represent the mean ± SD, n = 7–10 mice per group. * p < 0.05 and ** p < 0.01.

Article Snippet: Recombinant human FGF21 (rhFGF21) was purchased from Peprotech (Rocky Hill, NJ, USA), and recombinant murine FGF21 (rmFGF21) was purchased from Cusabio (Houston, TX, USA).

Techniques: Injection, Staining, Clinical Proteomics

Journal: International Journal of Molecular Sciences

Article Title: Recombinant FGF21 Attenuates Polychlorinated Biphenyl-Induced NAFLD/NASH by Modulating Hepatic Lipocalin-2 Expression

doi: 10.3390/ijms23168899

Figure Lengend Snippet: Recombinant FGF21 improves hepatic steatosis in PCB-induced NAFLD/NASH models. Aroclor1260- or PCB126-injected mice fed either a SD or HFD were intraperitoneally administered vehicle or rmFGF21 (1 mg/kg/day) once daily for 10 days. ( A , B ) Representative photograph images. ( C , D ) Liver weight. ( E ) H,E staining of liver tissue. Scale bar: 50 µm. ( F ) ORO staining and quantification showing that rhFGF21 (50 ng/mL, 24 h) reduced the hepatic lipid accumulation induced by both 20 μM Aroclor1260 and 10 μM PCB126 in O/P-treated human ARE primary hepatocytes. Scale bar: 50 µm. All values represent the mean ± SD, n = 4. * p < 0.05, ** p < 0.01 compared with the experimental control.

Article Snippet: Recombinant human FGF21 (rhFGF21) was purchased from Peprotech (Rocky Hill, NJ, USA), and recombinant murine FGF21 (rmFGF21) was purchased from Cusabio (Houston, TX, USA).

Techniques: Recombinant, Injection, Staining, Control

Journal: International Journal of Molecular Sciences

Article Title: Recombinant FGF21 Attenuates Polychlorinated Biphenyl-Induced NAFLD/NASH by Modulating Hepatic Lipocalin-2 Expression

doi: 10.3390/ijms23168899

Figure Lengend Snippet: Recombinant FGF21 attenuates hepatic iron overload in PCB-induced NAFLD/NASH models. Aroclor1260 (20 mg/kg)- or PCB126 (5 mg/kg)-injected mice fed either a SD or HFD were intraperitoneally administered vehicle or rmFGF21 (1 mg/kg/day) once daily for 10 days. ( A ) Prussian blue staining showing marked iron accumulation in liver samples. Scale bar: 50 μm. ( B ) Hepatic iron levels in PCB-induced NAFLD/NASH mice that were intraperitoneally administered vehicle or rmFGF21 (left panel, ferrous ion level; right panel, ferrous and ferric iron total levels). All values represent the mean ± SD, n = 7–10 mice per group. * p < 0.05 and ** p < 0.01. ( C ) Detection of intracellular ferrous ions (Fe 2+ ) using the fluorescent probe FerroFarRed in O/P- and FAC-cotreated HepG2 cells. Scale bar: 200 μm.

Article Snippet: Recombinant human FGF21 (rhFGF21) was purchased from Peprotech (Rocky Hill, NJ, USA), and recombinant murine FGF21 (rmFGF21) was purchased from Cusabio (Houston, TX, USA).

Techniques: Recombinant, Injection, Staining

Journal: International Journal of Molecular Sciences

Article Title: Recombinant FGF21 Attenuates Polychlorinated Biphenyl-Induced NAFLD/NASH by Modulating Hepatic Lipocalin-2 Expression

doi: 10.3390/ijms23168899

Figure Lengend Snippet: Recombinant FGF21 reduces PCB-induced overexpression of hepatic LCN2. Ten days after the rmFGF21 administration (1 mg/kg/day) in Aroclor1260- or PCB126-induced NAFLD/NASH mice, ( A ) real-time PCR and ( B ) western blot analysis were performed to detect mouse LCN2 in liver tissues from mice fed either a SD or HFD. The values represent the mean ± SD, n = six to eight mice per group. * p < 0.05 and ** p < 0.01. ( C ) Western blot analysis was performed to assess human LCN2 in 20 μM Aroclor1260- or 10 μM PCB126-treated HepG2 cells cotreated with either vehicle or rhFGF21 (50 ng/mL, 24 h).

Article Snippet: Recombinant human FGF21 (rhFGF21) was purchased from Peprotech (Rocky Hill, NJ, USA), and recombinant murine FGF21 (rmFGF21) was purchased from Cusabio (Houston, TX, USA).

Techniques: Recombinant, Over Expression, Real-time Polymerase Chain Reaction, Western Blot